SNPHY Stock Santen Pharmaceutical (SNPHY, $11.19) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 2, 2026

GET DAILY SIGNALS

Get AI intraday signals

SNPHY - Santen Pharmaceutical Co., Ltd.

MACD signal

View

Odds of DOWN Trend

Price: $11.19

Daily change: -$0.1 (-0.84%)

Daily volume: 12.6K

Capitalization: $3.6B

Industry: Pharmaceuticals: Major

This is a Bearish indicator signaling SNPHY's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 55 similar cases where SNPHY's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

SNPHY sees MACD Histogram just turned negative

SNPHY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where SNPHY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNPHY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SNPHY broke above its upper Bollinger Band on January 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 06, 2026. You may want to consider a long position or call options on SNPHY as a result. In of 125 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNPHY advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 200 cases where SNPHY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.059) is normal, around the industry mean (9.409). P/E Ratio (18.984) is within average values for comparable stocks, (24.389). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.865). Dividend Yield (0.022) settles around the average of (0.025) among similar stocks. P/S Ratio (2.045) is also within normal values, averaging (3.952).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNPHY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNPHY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.